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Abstract
Estrogen promotes breast cancer metastasis. However, the detailed mechanism remains largely unknown. The actin binding
protein ezrin is a key component in tumor metastasis and its over-expression is positively correlated to the poor outcome of
breast cancer. In this study, we investigate the effects of 17b-estradiol (E2) on the activation of ezrin and its role in estrogen-
dependent breast cancer cell movement. In T47-D breast cancer cells, E2 rapidly enhances ezrin phosphorylation at Thr
567 in
a time- and concentration-dependent manner. The signalling cascade implicated in this action involves estrogen receptor
(ER) interaction with the non-receptor tyrosine kinase c-Src, which activates the phosphatidylinositol-3 kinase/Akt pathway
and the small GTPase RhoA/Rho-associated kinase (ROCK-2) complex. E2 enhances the horizontal cell migration and
invasion of T47-D breast cancer cells in three-dimensional matrices, which is reversed by transfection of cells with specific
ezrin siRNAs. In conclusion, E2 promotes breast cancer cell movement and invasion by the activation of ezrin. These results
provide novel insights into the effects of estrogen on breast cancer progression and highlight potential targets to treat
endocrine-sensitive breast cancers.
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Introduction
Breast cancer is the most frequently diagnosed cancer in
women. Despite the recent improvements in survival rates, many
patients relapse and die for disseminated metastatic disease, which
supports the demand for new therapeutic strategies.
Female sex steroid estrogen is the fundamental regulator of
normal breast development. On the other side, the risk of breast
cancer is associated with early menarche, late menopause and
hormone replacement therapy (HRT) [1]. All these factors
increase the duration of exposure of breast tissue to estrogen,
which facilitates breast cancer initiation through multiple
established mechanisms [2]. In addition to this, clinical data
showed that the adjuvant therapy with aromatase inhibitors
reduces early distant metastasis and improves disease-free survival
[3], indicating that estrogen may facilitate the progression of breast
cancer. However, the mechanistic basis of estrogen on breast
tumor cell motility or invasion remains unclear.
Cell migration is required for cancer spread, invasion, and
metastasis. The primary mechanism for most types of cell
migration is the actin cytoskeleton remodeling [4]. In this process,
G-actin readily polymerizes to form F-actin and de novo actin
polymerization occurs at the leading edge, resulting in the
formation of membrane protrusions such as filopodia, lamellipodia
as well as invadopodia. The actin-binding ERM (ezrin/radixin/
moesin) proteins, concentrated in actin rich cell-surface structures,
are important regulators of actin reorganization by cross-linking
actin filaments with the plasma membrane [5]. We recently
discovered that sex steroids, including estrogen and progesterone,
promote endothelial as well as breast cancer cell migration by
inducing the formation of membrane protrusions [6,7,8,9]. These
events are dependent on the rapid activation of moesin, one
member of ERM family. However, moesin is found primarily in
endothelial cells whereas ezrin is concentrated in epithelial cells
[10,11]. Therefore, the role of ezrin in sex steroids-sensitive breast
cancer metastasis should not be neglected.
Clinical data have indicated the positive correlation between
ezrin expression/abnormal localization and advancing histological
grade/poor outcome [12,13]. Additionally, animal model exper-
iment demonstrated that the overexpression of wild-type ezrin
promotes breast cancer metastasis while expression of the
dominant-negative amino-terminal ezrin domain markedly inhib-
its metastasis [14]. In quiescent conditions ezrin exists in an auto-
inhibited conformation and phosphorylation on the carboxyl-
terminal threonine 567 (Thr
567) leads to ezrin activation, which
subsequently associates membrane associated adhesion molecules
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22439
26on ezrin’s NH2-terminal end and with polymerized F-actin on
ezrin’s COOH-terminal, leading to actin reorganization and the
formation of membrane structures [15]. Several protein kinases,
including protein kinase C, G protein-coupled receptor kinase 2
and Rho kinase have been proposed to mediate the threonine
phosphorylation of ezrin in vitro and/or in vivo [16,17,18].
However, whether ezrin activity is modulated by sex steroids is still
a matter of investigation.
In this manuscript, we explored the regulatory actions of
estrogen on ezrin activity and the effects on breast cancer cell
cytoskeleton remodeling, migration and invasion. Moreover, we
characterized the signaling pathways initiated by estrogen receptor
that lead to ezrin activation.
Results
E2 triggers a rapid phosphorylation of the actin-binding
protein ezrin
Treatment with E2 (10
28 M) on T47-D breast cancer cells
resulted in a rapid increase of Thr
567-phosphorylation of ezrin
(Fig. 1A). This phenomenon was time dependent and transient,
being maximal after 10–15 min and reversing to baseline after
60 min (Fig. 1A). Total ezrin did not change during this time
frame (Fig. 1A). Meanwhile, ezrin phosphorylation was found
throughout a range of E2 concentrations that fall within the
physiological range (Fig. 1B).
Thr
567-phosphorylation corresponds to ezrin activation [15]
and Tyr
353 phosphorylation is required for its full activation [19].
Indeed, when cells were exposed to different concentrations of E2
(10
210–10
26 M) for 15 min, Tyr
353 phosphorylation of ezrin was
significantly enhanced (Fig. 1C).
Likewise, in ER/PR positive MCF-7 breast cancer cells, E2
also provoked the rapid phosphorylation of ezrin on Thr
567,
suggesting that this action is generalized rather than cell specific
(Fig. 1D).
Actin fibers in T47-D breast cancer at baseline were arranged
longitudinally in the cytoplasm and the cell membrane was
regular. Treatment with E2 (10
28 M) resulted in a rapid shift of
t h ea c t i nf i b e r st o w a r dt h ee d g eo ft h em e m b r a n e( F i g .1 E ) .I n
parallel, cell membrane specialized structures, such as lamilli-
podia, were formed at sites enriched in actin where it
colocalized with phosphorylated ezrin (Fig. 1E). These effects
were visible in 15 minutes and began to revert after 30 minutes
(Fig. 1E).
ERa supports the extra-nuclear signaling of E2 to ezrin
The rapid time-lapse of ezrin activation and de-activation
suggests that it is likely to be mediated by extra-nuclear pathways
[20]. Indeed, activation of estrogen receptor (ER) with E2 still
resulted in ezrin activation even if RNA or protein synthesis was
blocked with actinomycin D (Act D - 10 mM) or cycloheximide
(CHX - 200 mM) (Fig. 2A). Likewise, estradiol-bovine serum
albumin conjugate (EBSA, 10
28 M), a membrane -impermeable
form of E2, also led to rapid activation of ezrin (Fig. 2A).
To identify which ER isoform is required for the signaling of E2
to ezrin, T47-D cells were treated with E2 (10
28 M), with the
preferential ERa agonist PPT (10
29 M) or with the ERb agonist
DPN (10
29 M). As shown in Fig. 2B, ezrin activation was
triggered only by E2 or PPT, which was largely prevented by the
addition of the pure ER antagonist ICI 182,780 (ICI - 1 mM). In
contrast, DPN failed to activate ezrin (Fig. 2B). These findings
indicate that ERa supports the signaling of E2 to ezrin while ERb
is not required.
ERa signaling to ezrin requires c-Src and
phosphatidylinositol-3-kinase (PI3K)/Akt
To clarify the implicated signaling intermediates, some of the
cascades responsible for extra-nuclear actions were interfered by
using signaling inhibitors. Consistently, E2-induced ezrin activa-
tion was prevented by ICI 182,780 (ICI - 1 mM) (Fig. 3A). On the
opposite, ezrin phosphorylation was not altered by the addition of
the mitogen-activated protein kinase kinase (MEK) inhibitor
PD98059 (PD - 5 mM) or of the G protein inhibitor pertussis
toxin (PTX - 100 ng/mL) (Fig. 3A). However, PI3K inhibitor
wortmannin (WM - 30 nM), Rho-associated kinase 2 (ROCK-2)
Y27632 (Y - 10 mM) and non-receptor tyrosine kinase c-Src
inhibitor PP2 (10 mM) all largely impaired E2-induced ezrin
activation (Fig. 3A), indicating that c-Src, PI3K and ROCK-2 are
required for this action.
To confirm the role of c-Src, the level of phospho- Tyr
416-Src,
which corresponds to its activation [21], was observed. Treatment
with E2 (10
28 M) led to an increase of phospho- Tyr
416-Src at 2 to
10 minutes and then it declined after 20 minutes (Fig. 3B). In
addition, c-Src phosphorylation was increased when cells were
treated with a range of E2 concentrations for 5 minutes (10
210–
10
26 M) (Fig. 3C). When c-Src expression was silenced with
specific siRNAs, E2 (10
28 M) failed to activate ezrin (Fig. 3D).
ERa interacts with the non-receptor tyrosine kinase c-Src and
this action links to the activation of PI3K [22]. This was confirmed
by our results showing that E2 (10
28 M) induced an increase of
phosphorylation of the PI3K downstream effector, protein kinase
Akt when compared to the vehicle-treated control (Fig. 3E). The
transfection with c-Src siRNA or the use of c-Src inhibitor PP2
both blocked E2-induced Akt phosphorylation (Fig. 3D, 3E),
suggesting that c-Src is the upstream of PI3K/Akt. In addition,
transfection of T47-D cells with a dominant negative form of the
regulatory subunit of PI3K, p85a (Dp85a), resulted in the
impairment of the E2-dependent ezrin activation (Fig. 3F). As
control, the transfection of a wild-type p85a construct (WT p85a)
did not alter ezrin activation (Fig. 3F). The p85 plasmids were
overexpressed in both conditions, implying an efficient transfection
in our experimental settings (Fig. 3F).Taken together; these results
suggest that the c-Src-dependent activation of PI3K/Akt is
implicated in E2-induced ezrin activation.
ER signaling to ezrin: role of RhoA and ROCK-2
The small GTPase RhoA and its downstream effector ROCK-2
play a central role in regulating the actin cytoskeleton by the
crosstalk to actin-regulatory proteins such as moesin or ezrin
[6,23]. Treatment of T47-D cells with E2 (10
28 M) increased the
amount of active, GTP-bound RhoA (Fig. 4A) and of functionally
activated ROCK-2, which was indicated by the enhanced Thr-
phosphorylation of the bait protein myelin basic protein (MBP) by
ROCK-2 immunoprecipitates (IPs) (Fig. 4B).
Transfection of a dominant negative RhoA construct (RhoA
T19N-RhoA DN) led to a significant reduction of E2-induced
ezrin phosphorylation (Fig. 4C). In constrast, ezrin phosphoryla-
tion was ligand-independently induced by transient transfection of
a RhoA constitutively-active construct (RhoA G14V-RhoA CA)
(Fig. 4C). Meanwhile, silencing of ROCK-2 with siRNAs
prevented the E2-dependent ezrin activation (Fig. 4D).
The activation of RhoA/ROCK-2 is mediated by c-Src and
PI3K, since inhibitors of both kinases blocked the activation of
RhoA and ROCK-2 by E2 (Fig. 4A, 4B). In line with this, c-Src
silencing with siRNAs blocked E2-induced RhoA and ROCK-2
activation(Fig. 4E), which was also impaired by transfection with
Dp85a (Fig. 4F). In contrast, RhoA activation was ligand-
independently increased after transfection of WT p85a (Fig. 4F).
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22439Figure 1. E2 activates ezrin and induces rapid actin cytoskeleton rearrangement in T47-D cells. (A) and (B) show the time- and dose-
dependent ezrin activation in T47-D breast cancer cells after treatment with E2. Total cell amount of wild-type (ezrin) or Thr
567-phosphorylated ezrin
(P-ezrin) are shown with western blot. P-ezrin densitometry values were adjusted to ezrin intensity, then normalized to expression from the control
sample. *=P,0.05 vs. corresponding control; **=P,0.01 vs. corresponding control. (C) shows dose-dependent ezrin phosphorylation at Tyr
353 after
treatment with E2 for 15 minutes in T47-D cells. Tyr
353-phosphorylated ezrin (P-ezrin) are shown with western blot and actin is taken as the loading
control. (D) In MCF-7 breast cancer cells, E2 induced ezrin phosphorylation at Thr
567 in a time-dependent manner. (E) T47-D cells were treated with E2
(10
28 M) for the indicated time. Then the cells were stained with anti-phospho-Thr
567 ezrin (P-ezrin) linked to FITC. Actin was stained with phalloidin
linked to Texas Red and nuclei were counterstained with DAPI. White arrows indicate the lamellipodia. All the experiments were repeated three times
with consistent results, and the representative images are shown.
doi:10.1371/journal.pone.0022439.g001
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migration and invasion
Finally we observed the role of ezrin activation in estrogen-
sensitive breast cancer cell migration and invasion. To this aim,
we silenced ezrin expression by using 2 different ezrin siRNAs.
Indeed, ezrin expression was largely repressed by the transfec-
tion of both siRNAs, as indicated in Fig. 5A. Furthermore, we
detected the cellular ezrin expression by using immunofluore-
sence and it showed that the immunostaining was extremely weak
in specific ezrin siRNA transfected cells, in association with a very
regular arrangement of actin fibers (Fig. 5B). Consistent with our
previous work [7], E2 markedly enhanced horizontal migration
(Fig. 5C). This effect was completely blocked by silencing ezrin
with siRNAs (Fig. 5C). The enhancement of cancer cell migration
induced by E2 was also prevented by blocking ER with ICI
182,780, by blocking c-Src with PP2, PI3K with wortmannin or
ROCK-2 with Y-27632 (Fig. 5D). E2 promoted breast cancer cell
invasion of a three-dimensional matrix (Fig. 5E). The invasive
behavior induced by E2 was prevented by silencing ezrin with
siRNAs, and by the inhibitors of ER, c-Src and PI3K cascades
(Fig. 5E).
Discussion
Estrogen stimulates cell movement in different tissues, including
the mammary gland. It also promotes ER
+ breast cancer cell to
invade and metastasize to lymph nodes and distant organs [24].
The key finding of the present manuscript is that estrogen signals
to ezrin and induces its phosphorylation, which contributes to the
enhanced ability of ER
+ breast cancer cells to migrate and invade
the surrounding environment. In parallel, it has been reported that
ezrin phosphorylation is required for androgen-induced prostate
cancer cell invasion [19]. Taken together, these findings help to
understand the basis through which sex steroids drives gender-
related cancers metastasis and may herald profound biological and
medical implications.
Cell movement is a highly integrated process implemented by
actin reorganization [25]. Rearrangement of actin fibers is crucial
to the formation of membrane protrusions at the leading edge.
This process is modulated by sex steroids in human cells, including
endothelial and breast cancer cells where estrogen significantly
increases the number of membrane lamellipodia and filopodia.
These events are linked to the rapid activation of actin-binding
protein moesin, which belongs to the ezrin/radixin/moesin (ERM)
family [6,7,8,9]. Notwithstanding, evidence on the link between
moesin and clinical feature of cancer is limited, while more clinical
trials focus on the role of ezrin in different types of cancer
progression, including in breast cancer [26,27,28]. For example,
clinical data have indicated the positive correlation between ezrin
expression/abnormal localization and advancing histological
grade/poor outcome [12,13]. Moreover, the overexpression of
wild-type ezrin is shown to promote breast cancer metastasis in
animal model experiment [14]. Overall, these findings highlight
the relevance of the ezrin activity for breast cancer progression.
The identification of ezrin regulation may thus offer important
mechanistic insights to breast cancer metastasis.
We here find that E2 rapidly activates Thr
567 and Tyr
353
phosphorylation of ezrin, leading to the actin cytoskeleton
remodelling and the formation of lamellipodia and filopodia. In
quiescent conditions ezrin exists in an auto-inhibited conforma-
tion. Unfolding of the molecule into an active conformation occurs
following binding to phosphoinositides and phosphorylation on the
carboxyl-terminal Thr
567 [15]. The active ezrin then translocates
to the plasma membrane and functions as a molecular bridge by
binding membrane associated adhesion molecules and polymer-
ized F-actin [29], resulting in actin cytoskeleton remodelling. This
is confirmed by our immunofluorescent results showing that
phosphorylated ezrin clusters in cell membrane lamillipodia and
filopodia. It has been reported that ezrin silencing by small hairpin
RNA or the expression of dominant-negative amino-terminal
ezrin reverses metastatic behaviors of human breast cancer cells
[14,30,31]. In agreement, in the present study the silencing of
Figure 2. ERa supports the extra-nuclear signaling of E2 to ezrin. (A) T47-D cells were treated with E2 (10
28 M) or E-BSA (10
28 M) for 15 min,
in the presence or absence of actinomycin D (Act D - 10 mM) or cycloheximide (CHX - 200 mM). Ezrin and phosphorylated ezrin are shown. **=P,0.01
vs control. (B) T47-D cells were treated with E2 (10
28 M), PPT (10
29 M) or DPN (10
29 M) for 15 min, in the presence or absence of ICI 182,780 (ICI -
1 mM). Ezrin and phosphorylated ezrin are shown. **=P,0.01 vs. control. #=P,0.01 vs. E2 or PPT, respectively. All the experiments were repeated
three times with consistent results, and the representative images are shown.
doi:10.1371/journal.pone.0022439.g002
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22439ezrin by small interference RNA largely impairs E2-dependent cell
migration and invasion. The active ezrin is also capable to recruit
the guanine nucleotide exchange factor Dbl to lipid rafts and
preferentially activates Cdc42, which is important for directional
breast cancer cell migration [32].
The activation of ezrin induced by E2 is achieved via extra-
nuclear signaling cascades. Such mechanisms of actions depend on
the recruitment of kinase cascades via the interaction of membrane
ERs with specific domains of kinases, such as c-Src or PI3K [33].
Indeed, the existence of membrane-localized ERs in different
tissues is well documented [34]. Although the definition of the
exact intracellular E2-binding site is beyond the scope of this
manuscript, there is a chance that a membrane-initiated process
might be activated in this setting. In general, membrane receptor-
initiated nongenomic effects have several characteristics, including
the rapid time course and insensitive to mRNA and protein
synthesis inhibitors [35]. Consistently, ezrin activation is rapid,
which could be found after exposure to E2 for 5 minutes and this
Figure 3. c-Src and phosphatidylinositol-3-kinase (PI3K)/Akt are implicated in E2-induced ezrin phosphorylation. (A) T47-D cells were
exposed to 10
28 M E2 for 15 min, in the presence or absence of the pure ER antagonist ICI 182,780 (ICI - 1 mM), of the MEK inhibitor PD98059 (PD -
5 mM), of the G protein inhibitor, PTX (100 ng/mL), of the PI3K inhibitor wortmannin (WM - 30 nM), of the ROCK-2 inhibitor, Y-27632 (Y - 10 mM) or of
the c-Src kinase inhibitor, PP2 (10 mM). Cell content of wild-type or phosphorylated ezrin are shown. P-ezrin densitometry values were adjusted to
ezrin intensity and then normalized to expression from the control sample. **=P,0.01 vs. control, #=P,0.01 vs. E2. (B) and (C) show the time- and
dose-dependent c-Src activation in T47-D breast cancer cells after treatment with E2. Total cell amount of wild-type (c-Src) or Tyr
416-phosphorylated
c-Src (P-c-Src) are shown with western blot. P-c-Src densitometry values were adjusted to c-Src intensity, then normalized to expression from the
control sample. (D) T47-D cells were exposed to 10
28 M E2 for 15 min after transfection with 100 nM c-Src siRNAs or control scrambled siRNAs for
48 h. Total actin, c-Src, ezrin, P-ezrin, Akt and P-Akt amounts and statistics for densitometry are shown. **=P,0.01 vs. corresponding control. (E) T47-
D cells were treated with 10
28 M E2 for 15 min, with or without the ER antagonist ICI 182,780 (ICI - 1 mM), PI3K inhibitor wortmannin (WM - 30 nM) or
c-Src kinase inhibitor, PP2 (10 mM). Active Akt (P-Akt) densitometry values were adjusted to wild-type Akt intensity, then normalized to expression
from the control sample. **=P,0.01 vs. control. #=P,0.01 vs. P. (F) Cells were exposed to 10 nM E2 for 15 min after transfection with wild type
p85a (WT p85a, 1.5 mg) or dominant-negative p85a (Dp85a, 1.5 mg) for 48 h. Cell contents of actin, p85 protein, wild-type and phosphorylated ezrin
and statistics for densitometry are shown. **=P,0.01 vs. corresponding control without transfection. All these experiments were performed in
triplicates and representative images are shown.
doi:10.1371/journal.pone.0022439.g003
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phosphorylation of ezrin is biphasic and this pattern of kinetics is
similar to other nongenomic actions of sex steroids, such as the
biphasic release of calcium [36]. The reasons for the biphasic action
may be due to the rapid accumulation of second messengers when
sex steroids bind to their membrane receptors.Indeed,inthe present
study, c-Src phosphorylation is rapidly enhanced after 2 minutes of
exposure to E2 and then it gradually declines, which could explain
the time-dependent attenuation of ezrin phosphorylation.
Notwithstanding, we do not exclude the longterm effects of E2
on cell migration and invasion, since it has been reported that
ezrin expression is induced by E2 in other tissues [37,38]. This
Figure 4. RhoA and ROCK-2 are activated during ER signaling to ezrin. (A) RhoA activity was assayed in cells treated with E2 (10
28 M) for
15 min in the presence or absence of the ICI 182,780 (ICI - 1 mM), of the PI3K inhibitor wortmannin (WM - 30 nM), or of the c-Src kinase inhibitor, PP2
(10 mM). Active, GTP-bound RhoA was immunoprecipitated with Rhotekin and subsequently assayed with western analysis with an anti-RhoA Ab
(lower boxes). The upper blot shows total RhoA content in the input. RhoA-GTP densitometry values were adjusted to total RhoA intensity, then
normalized to expression from the control sample. **=P,0.01 vs. control. #=P,0.01 vs. E2. (B) Cells were treated with 10
28 M E2 for 15 min in the
presence or absence of ICI 182,780 (ICI - 1 mM), of wortmannin (WM - 30 nM) or of PP2 (10 mM). ROCK-2 was immunoprecipitated with a specific Ab
and the IPs were used to phosphorylate the bait protein, myelin basic protein (MBP). ROCK-2 kinase activity is shown as the amount of
phosphorylated MBP (P-MBP). P-MBP densitometry values were adjusted to ROCK-2 intensity, then normalized to expression from the control sample.
**=P,0.01 vs. control. #=P,0.01 vs. E2. (C) T47-D cells were either mock-transfected or exposed to dominant-negative RhoA or constitutively
active (RhoA DN or RhoA CA). Cells were then treated with E2 (10 nM) for 15 min and wild type or phosphorylated ezrin were analyzed. P-ezrin
densitometry values were adjusted to actin intensity, then normalized to expression from the corresponding control sample. **=P,0.01 vs.
corresponding control without transfection. (D) Cells were exposed to 10
28 M E2 for 15 min after transfection with 100 nM siRNAs towards ROCK-2
or control scrambled siRNAs for 48 h. P-ezrin densitometry values were adjusted to ezrin intensity, then normalized to expression from the
corresponding control sample. **=P,0.01 vs. corresponding scrambled control. (E) Cells were exposed to 10
28 M E2 for 15 min after transfection
with c-Src siRNAs for 48 h. Active, GTP-bound RhoA and ROCK-2 activity were assayed RhoA-GTP and P-MBP densitometry values were adjusted to
total RhoA and ROCK-2 intensities respectively, then normalized to expression from the control sample. **=P,0.01 vs. control. All these experiments
were performed in triplicates and representative images are shown.
doi:10.1371/journal.pone.0022439.g004
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nuclear action (such as the rapid ezrin activation) to the relevant
physiologic consequences (such as the cell movement), since the
blockade of the nuclear signalings, gene transcription and protein
translation will negatively impact cell viability. In this regard, a
recent study provided the first in vivo evidence that extra-nuclear
ER actions prevent neointima formation in mice model by using
the estrogen-dendrimer conjugate (EDC), a novel selective ER
modulator (SERM) capable of exclusive non-nuclear action [39].
Therefore, the new generation of SERM, such as EDC, should be
used in the future studies to address the role of extra-nuclear ER
actions in hormone-sensitive breast cancer cell invasiveness.
Several signalling molecules, such as phosphatidylinositol 4,5 bis-
phosphate (PIP2) and protein kinase C (PKC), have been implicated
in regulating ezrin protein activity [40,41]. The present work
indicates that the non-receptor tyrosine kinase c-Src acts as a central
hub in relaying ER signalling to ezrin activation. Indeed, c-Src plays
important role in breast cancer cell proliferation, survival, invasion,
and metastasis [42] and its activity is modulated by estrogen through
multiple mechanisms. For example, c-Src is recruited and activated
by the interaction of membrane ER with several scaffold proteins,
such as MNAR/PELP1 and striatin [43]. Recently it has been shown
that estrogen activates c-Src through the release of nitric oxide (NO),
leading to breast cancer cell invasion and metastasis [44].
Figure 5. Estrogen signaling to ezrin increases T47-D cell migration and invasion. (A) T47-D cells were transfected with scrambled siRNA or
ezrin targeted siRNA 1 and 2 for 48 h. Ezrin protein expression was detected by western blot and b-actin intensity was used as the loading control as
indicated. (B) Cells were stained with an Ab vs. ezrin (FITC; green staining) as well as with Texas Red-phalloidin (in red). Nuclei are counterstained in
blue. All the experiments were repeated three times with consistent results, and a representative result is shown. (C) Cells were transfected with
100 nM target siRNAs for ezrin or scrambled siRNA for 48 h and then treated with E2 (10 nM) for 48 h. Cell migration distances were measured and
values are presented within brackets as mean migration distance (mm) 6 SD. The black line indicates the starting line. *=P,0.01 vs. control. (D) Cells
were treated with E2 (10 nM) for 48 h, in the presence or absence of ICI 182,780 (ICI - 1 mM), of wortmannin (WM - 30 nM), of Y-27632 (Y - 10 mM) or
of PP2 (10 mM). *=P,0.01 vs. control; #=P,0.01 vs. E2. The experiments were performed in triplicates and representative images are shown. (E)
T47-D cells were treated with 10 nM E2 for 24 h, in the presence or absence of ICI 182,780 (ICI - 1 mM), of wortmannin (WM - 30 nM), of Y-27632 (Y -
10 mM), of PP2 (10 mM) or after transfection with 100 nM siRNAs toward ezrin or control scrambled siRNAs for 48 h. Cell invasion was assayed using
invasion chambers. Invading cells were counted in three different central fields of triplicate membranes. Statistics for invasion indexes and
representative images are shown. *=P,0.01 vs. control, #=P,0.01 vs E2 without transfection. The experiments were performed in triplicates and
representative images are shown.
doi:10.1371/journal.pone.0022439.g005
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In our experimental setting, we identify that PI3K is the
downstream of c-Src, and this step is necessary for ezrin activation,
based on our findings showing that the transfection of Dp85a led
to a significant reduction of E2-induced ezrin phosphorylation,
while which was enhanced by transient transfection of WT p85a.
Moreover, transfection with WT p85a induced a ligand-
independent increase of ezrin phoshorylation, since the enhanced
expression of this regulatory subunit leads to an increase of basal
phoshorylated Akt [46].
This is consistent with clinical data indicating that the level of
phosphorylated ezrin or the membranous ezrin staining is
positively associated with the phosphorylated Akt overexpression
[13,47]. Moreover, Akt is believed to govern breast cancer
metastasis, which is partly due to its modulation on ezrin
phosphorylation and localization [48]. Interestingly, c-Src/PI3K
can also function as the downstream cascade of ezrin to maintain
cell survival or to promote breast cancer metastasis [14,49].
Therefore, a positive feedback loop might exist between c-Src/
PI3K and ezrin in breast cancer.
ER-dependent PI3K activation results in the activation of the
RhoA/ROCK-2 cascade and through this manner it increases
ezrin activity in breast cancer cells. A similar role of the RhoA/
ROCK cascade has been established in fibroblast and in other
tumor cells, where it mediates ezrin activation or redistribution
[23,50,51]. However, the precise mechanism by which ROCK
phosphorylates ezrin is not clear in this study. To this extent, there
is evidence that ROCK binds and phosphorylates ERM directly
[52], while other report shows that ROCK is not responsible for
threonine phosphorylation of ezrin [53,54].
Phosphorylation of ezrin is required for both conformational
activation and for signaling to downstream events. Although
RhoA/ROCK mediates some of the signal transduction between c-
Src/PI3K to ezrin Thr
567 phosphorylation, it may also be possible
that c-Src directly interacts with ezrin and results in the
phosphorylation of other residues in the presence of E2, like the
Tyr
353 phosphorylation indicated inthe present study. In fact, c-Src
is reported to directly phosphorylate ezrin at different sites, such as
Tyr
145 [55], Tyr
353 [19] and Tyr
477 [56]. For instance, it has been
shown that in cells lacking Src, ezrin is not tyrosine-phosphorylated
but the introduction of active c-Src restores its phosphorylation
[56]. In addition, activation of c-Src results in ezrin phosphoryla-
tion and the Src tyrosine kinase inhibitorPP2 blocks this effect [57].
Although the phosphorylation of these tyrosine sites exerts different
functions, recent data indicated that Tyr
353 is an important site
required for ezrin full activation of ezrin [19]. It showed that sex
steroid androgen indirectly phosphorylates ezrin at Thr
567 via PKC
pathway and directly phosphorylates Tyr
353 via c-Src, leading to
ezrin full activation and promoting prostate cancer cell invasion
[19]. Therefore, it is possible that E2 indirectly phosphorylates
ezrin Thr
567 via c-Src/PI3K/Akt/RhoA/ROCK-2 cascade and
phosphorylates ezrin Tyr
353 via a direct interaction of c-Src and
ezrin. The full characterization of the functional interrelation
between c-Src and ezrin during estrogen exposure is therefore not
solved and will require future studies.
As we mentioned before, the mechanisms that estrogen affects
breast cancer metastasis are complex, including nongenomic and
genomic actions. Through nongenomic activation of actin-binding
proteins, including moesin [7] and focal adhesion kinase [58],
estrogen rapidly provoke actin cytoskeleton reorganization in
breast cancer cells, leading to the formation of membrane
specialized structures that facilitate breast cancer cell migration
and invasion, as we indicated in this work. Meanwhile, estrogen
transactivate receptor tyrosine kinases (including epidermal growth
factor receptor and insulin-like growth factor receptor), resulting in
growth factor-like effects that transform cancer cell into an
invasive phenotype [59]. Moreover, the expression patterns of
metastasis-associated molecules, such as cell adhesion molecule E-
cadherin [60], matrix metalloproteinases [61], growth factors
[62,63], chemokines and their receptors [64,65], are reported to
be regulated by estrogen, leading to epithelial-to-mesenchymal-like
transition and promoting breast cancer cells escape from primary
site and migrate toward target tissues and organs. In this study, we
show that E2 promotes breast cancer cell movement and invasion
by the rapid activation of ezrin. In the presence of E2, ER
activates c-Src and PI3K/Akt, leading to RhoA/ROCK-2
activation, which eventually phosphorylates ezrin at Thr
567. Our
results provide original mechanistic insights into the effects of E2
on breast cancer progression and may in the future be helpful to
develop new drugs against endocrine-sensitive breast cancers.
Materials and Methods
Cell cultures and treatments
T47-D breast cancer cells were obtained from China Center for
Type Culture Collection (www.cctcc.org) and incubated in phenol
red-free RPMI 1640 medium containing 10% fetal calf serum
(FCS), 0.2 UI/mL insulin, L-glutamine and penicillin streptomycin
under a 5% CO2 atmosphere at 37uC. Before experiments
investigating non-transcriptional effects, cells were kept in phenol
red-free DMEM containing no FBS for 8 hours. Whenever an
inhibitor was used, the compound was added 30 minutes before
starting the treatments. 17b-estradiol (E2), pertussis toxin (PTX), Y-
27632, PD98059 and wortmannin were from Sigma-Aldrich (Saint-
Louis, MO). 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo (3,4-d)
pyrimidine (PP2) was from Calbiochem (EMD Biosciences,
Germany). 49,40,490-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol
(PPT), 2,3-bis-(4–ydroxyphenyl)-propionitrile (DPN) and ICI 182
780 were purchased from Tocris Cookson (Bristol, UK).
Immunoblottings
Cell lysates were separated by SDS-PAGE. Antibodies used
were: phospho-Thr
567-Ezrin (A00334, Genescript, Aachen, Ger-
many), ezrin (#3145 ,Cell signaling), phospho- Tyr
416-Src (#
2101, Cell Signalling Technology), Src (# 2108, Cell signaling) ,
ROCK-2 (C-20, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), phosphor- Ser
473- Akt (Upstate Biotechnology, Inc., Lake
Placid, NY), actin (sc-1615, Santa Cruz), Akt (# 9272, Cell
Signalling Technology). Primary and secondary Abs were
incubated with the membranes with standard technique. Im-
munodetection was accomplished using enhanced chemilumines-
cence. Chemiluminescence was acquired with a quantitative
digital imaging system (Quantity One, BioRad, Hercules, CA)
allowing to check for saturation. Overall emitted photons were
quantified for each band, particularly for loading controls, which
were homogeneously loaded.
Kinase assays
T47-D cells were harvested in 20 mM Tris-HCl, 10 mM
EDTA, 100 mM NaCl, 0.5% IGEPAL and 0.1 mg/mL PMSF.
Equal amounts of cell lysates were immunoprecipitated with
Rhotekin RBD agarose (Rhotekin is the protein that binds
specifically to GTP-bound, and not GDP-bound, RhoA. The
Rhotekin-RBD contains residues 7–89 of Rhotekin. This region
includes the sequences required for the high affinity interaction
with GTP-Rho. # 14-383, upstate) vs. GTP-RhoA or an Ab vs.
ROCK-2 (C-20, Santa Cruz). The IPs were washed three times
with buffer containing 20 mM Tris-HCl, 10 mM EDTA,
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ROCK-2 activity assay, two additional washes were performed in
kinase assay buffer (20 mM MOPS, 25 mM b-glycerophosphate,
5 mM EGTA, 1 mM DTT) and the samples were therefore
resuspended in this buffer. 5 mg of de-phosphorylated myelin basic
protein (Upstate) together with 500 mM ATP and 75 mM MgCl2
were added to each sample and the reaction was started at 30uC
for 20 min. The reaction was stopped on ice and by resuspending
the samples in Laemmli Buffer. The samples were separated with
SDS-PAGE and Western analysis was performed using antibodies
recognizing RhoA (sc-418, Santa Cruz) or Thr
98-P-myelin basic
protein (05-429, Upstate).
Cell immunofluorescence
T47-D breast cancer cells were grown on coverslips and
exposed to treatments. Cells were fixed with 4% paraformalde-
hyde for 30 min and permeabilized with 0.1% Triton X for 5 min.
Blocking was performed with 3% normal serum for 20 min. Cells
were incubated with antibody against phospho-Thr
567-Ezrin
(A00334, Genescript) and FITC-conjugated secondary antibody
(K00018968, Dako North America Inc., Dako, Denmark). After
washing the nuclei were counterstained with 49-6-diamidino-2-
phenylindole (DAPI) (Sigma) and actin was stained with Texas
Red-phalloidin (Sigma). The coverslips were mounted with
Vectashield mounting medium (Vector Laboratories, Burlingame,
CA). Immunofluorescence was visualized using an Olympus BX41
microscope and recorded with a high-resolution DP70 Olympus
digital camera. Pictures were photographed.
Transfection experiments
On-TARGETplus SMARTpool siRNA reagents against hu-
man Src (NM-198291), ROCK-2 (NM-004850), ezrin (NM-
017370, siRNA 1) and control siRNA (D-001810-01-05) were
purchased from Dharmacon (Thermo Fisher Scientific Inc, USA).
In order to eliminate the off-target effect, another ezrin siRNA (sc-
35349, siRNA 2) purchased from Santa Cruz was also used. T47-
D cells were transfected with siRNA using Lipofectamine
(Invitrogen) according to the protocol. Cells (40% confluent) were
serum-starved for 1 h followed by incubation with 100 nM target
siRNA or control siRNA for 6 h in serum-free media. The serum-
containing media was then added (10% serum final concentration)
for 42 h before experiments and/or functional assays were
conducted. Target protein silencing was assessed through protein
analysis up to 48 h after transfection.
Each plasmid (15 mg) was transfected into T47-D breast cancer
cells using the Lipofectamine (Invitrogen) according to the
manufacturer’s instructions. The transfected plasmids were as
follows: RhoA T19 and RhoA G14V, p85a or dominant-negative
p85a (D p85a). These constructs were obtained from the Guthrie
cDNA Resource Center (www.cdna.org). All the inserts were
cloned in pcDNA3.1+. As control, parallel cells were transfected
with empty pcDNA3.1+ plasmid. Cells (60–70% confluent) were
treated 24 h after transfection, and cellular extracts were prepared
according to the experiments to be performed.
Cell migration assays
Cell migration was assayed with razor scrape assays as
previously described [9]. Briefly, a razor blade was pressed
through the confluent T47-D breast cancer cell monolayer into the
plastic plate to mark the starting line. T47-D cells were swept away
on one side of that line. Cells were washed, and 2.0 mL of DMEM
containing steroid-deprived FBS and gelatin (1 mg/mL) were
added. Cytosine b-D-arabinofuranoside hydrochloride (Ara-C,
Sigma) (10 mM), a selective inhibitor of DNA synthesis which does
not inhibit RNA synthesis was used 1 h before the test substance
was added. Ara-C is easy to enter into the cellular nucleus and it
incorporates into DNA and inhibits DNA replication by the
formation of cleavage complexes with topoisomerase I resulting in
DNA fragmentation. Although the half-life of Ara-C was less than
1 h in most of the cell lines, more than 80% of Ara-C DNA was
retained at 24 h after drug removal [66]. Migration was
monitored for 48 hours. Every 12 h fresh medium and treatment
were replaced. Cells were digitally imaged and migration distance
(mm) was measured by using phase-contrast microscopy.
Cell invasion assays
Cellinvasionwereassayedfollowing thestandard methodbyusing
the BD BioCoatTM Growth Factor Reduced (GFR) Matrigel
TM
Invasion Chamber (BD Bioscience, USA). In brief, after rehydrating
the GFR Matrigel inserts, the test substance was added to the wells.
An equal number of Control Inserts (no GFR Matrigel coating) were
prepared ascontrol.0.5 mLofT47-Dcellsuspension(2.5610
4cells/
mL) were added to the inside of the inserts. The chambers were
incubated for 24 h at 37uC, 5% CO2 atmosphere. After incubation,
non-invading cells were removed from the upper surface of the
membrane using cotton tipped swabs. Then the cells on the lower
surface of the membrane were stained with Diff-Quick stain. The
invading cells were observed and photographed under the
microscope at 1006magnification. Cells were counted in the central
field of triplicate membranes. The invasion index was calculated as
the % invasion test cell/% invasion control cell.
Statistical analysis
All values are expressed as mean 6 SD. Statistical differences
between mean values were determined by ANOVA, followed by
the Fisher’s protected least significance difference (PLSD). All
differences were considered significant at P,0.05.
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